ES2187667T3 - Uso de relaxina para estimular angiogenesis. - Google Patents

Uso de relaxina para estimular angiogenesis.

Info

Publication number
ES2187667T3
ES2187667T3 ES96928212T ES96928212T ES2187667T3 ES 2187667 T3 ES2187667 T3 ES 2187667T3 ES 96928212 T ES96928212 T ES 96928212T ES 96928212 T ES96928212 T ES 96928212T ES 2187667 T3 ES2187667 T3 ES 2187667T3
Authority
ES
Spain
Prior art keywords
relaxin
stimulate angiogenesis
angiogenesis
infections
lack
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96928212T
Other languages
English (en)
Inventor
Elaine Unemori
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Connetics Corp
Original Assignee
Connetics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Connetics Corp filed Critical Connetics Corp
Application granted granted Critical
Publication of ES2187667T3 publication Critical patent/ES2187667T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

LA RELAXINA ES UTIL PARA PROMOVER LA ANGIOGENESIS Y EL TRATAMIENTO DE INFECCIONES DE HERIDAS ISQUEMICAS EN LAS QUE LA LESION TIENE COMO RESULTADO LA FALTA DE OXIGENO DEBIDO A UNA MALA CIRCULACION.
ES96928212T 1995-08-15 1996-08-15 Uso de relaxina para estimular angiogenesis. Expired - Lifetime ES2187667T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US235595P 1995-08-15 1995-08-15

Publications (1)

Publication Number Publication Date
ES2187667T3 true ES2187667T3 (es) 2003-06-16

Family

ID=21700396

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96928212T Expired - Lifetime ES2187667T3 (es) 1995-08-15 1996-08-15 Uso de relaxina para estimular angiogenesis.

Country Status (9)

Country Link
US (3) US6211147B1 (es)
EP (1) EP0845992B1 (es)
JP (1) JP4568383B2 (es)
AT (1) ATE228004T1 (es)
AU (1) AU6777196A (es)
CA (1) CA2229479C (es)
DE (1) DE69624925T2 (es)
ES (1) ES2187667T3 (es)
WO (1) WO1997006814A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001236886A1 (en) * 2000-02-09 2001-08-20 Connetics Corporation Use of relaxin to treat diseases related to vasoconstriction
ITRM20020119A1 (it) * 2002-03-05 2003-09-05 Geymonat Spa Composizioni contenenti plgf ad uso farmaceutico e cosmetico.
US7878978B2 (en) * 2004-03-18 2011-02-01 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Use of relaxin to increase arterial compliance
AU2005223694B2 (en) * 2004-03-19 2011-04-28 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Use of relaxin to increase arterial compliance
US7553813B2 (en) * 2004-04-30 2009-06-30 Corthera, Inc. Methods and compositions for control of fetal growth via modulation of relaxin
EP1877065A4 (en) * 2005-04-12 2010-12-22 Intradigm Corp COMPOSITION OF INTERFERENT RNA THERAPEUTIC AGENTS (RNAi) AND METHODS FOR TREATING CANCER AND OTHER NEOVASCULARIZATION DISEASES
US7893244B2 (en) * 2005-04-12 2011-02-22 Intradigm Corporation Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
US20060281669A1 (en) * 2005-06-13 2006-12-14 Yue Samuel K Method and compositions for the treatment of diabetes and related complications
WO2007027168A1 (en) * 2005-08-29 2007-03-08 Carrier Corporation Compressor muffler
US8986253B2 (en) 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
EP2288367B1 (en) * 2008-05-16 2015-10-07 Corthera, Inc. H2 relaxin for use in the treatment of premature cervical dilation
WO2009140433A1 (en) * 2008-05-16 2009-11-19 Corthera, Inc. Method of promoting wound healing
CA2724540C (en) 2008-05-16 2014-07-08 Corthera, Inc. Treating dyspnea associated with acute heart failure with relaxin
BRPI0805852A8 (pt) * 2008-09-05 2021-06-29 Univ Rio De Janeiro polímeros ácidos protéicos, processos de produção, uso de polímeros ácidos protéicos, composição farmacêutica e método de tratamento
US8408421B2 (en) 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
AU2009293019A1 (en) 2008-09-19 2010-03-25 Tandem Diabetes Care Inc. Solute concentration measurement device and related methods
CA2769030C (en) 2009-07-30 2016-05-10 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
BR112013003522B1 (pt) 2010-08-17 2021-05-25 Ambrx, Inc. polipeptídeos relaxina modificados compreendendo um aminoácido não codificado naturalmente, seu método de preparação e seu uso, bem como ácido nucleico e célula hospedeira
WO2013033324A2 (en) * 2011-08-31 2013-03-07 University Of Florida Research Foundation, Inc. Materials and methods for modulating activity of bone marrow derived cells
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
US9555186B2 (en) 2012-06-05 2017-01-31 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
US9526762B1 (en) * 2013-08-09 2016-12-27 William Marsh Rice University Multidomain peptides for promoting angiogenesis
DK3387019T3 (da) 2015-12-09 2022-01-10 Scripps Research Inst Relaxin-immunoglobulinfusionsproteiner og anvendelsesfremgangsmåder

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023321A (en) * 1982-12-13 1991-06-11 Howard Florey Institute Of Experimental Physiology & Medicine Molecular cloning and characterization of a further gene sequence coding for human relaxin
US5023088A (en) * 1987-06-25 1991-06-11 Alza Corporation Multi-unit delivery system
WO1989007945A1 (en) 1988-02-26 1989-09-08 Genentech, Inc. Human relaxin formulation
GB8907799D0 (en) * 1989-04-06 1989-05-17 Erba Carlo Spa Heteroaryl-3-oxo-propanenitrile derivatives useful in the treatment of rheumatoid arthritis and other autoimmune diseases
CA2051375C (en) 1989-05-04 2000-09-12 Dennis J. Henner Process and compositions for the isolation of human relaxin
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5166191A (en) 1991-08-19 1992-11-24 Genentech, Inc. Use of relaxin in cardiovascular therapy
US5478807A (en) 1991-08-19 1995-12-26 Genentech, Inc. Use of relaxin in the treatment of bradycardia
US5952296A (en) 1993-07-27 1999-09-14 Bigazzi; Mario Method of using relaxin as therapeutic or preventing agent
US5753623A (en) * 1995-06-07 1998-05-19 Connetics Corporation Method of treatment for depression
US5911997A (en) 1995-06-07 1999-06-15 Connetics Corporation Relaxin-like factor and methods and uses thereof
US5811395A (en) * 1995-06-07 1998-09-22 Medical University Of South Carolina Relaxin analogs and derivatives methods and uses thereof

Also Published As

Publication number Publication date
WO1997006814A1 (en) 1997-02-27
JP4568383B2 (ja) 2010-10-27
EP0845992A1 (en) 1998-06-10
JPH11511174A (ja) 1999-09-28
EP0845992B1 (en) 2002-11-20
DE69624925T2 (de) 2003-09-04
CA2229479C (en) 2010-03-30
CA2229479A1 (en) 1997-02-27
US20010018418A1 (en) 2001-08-30
US6780836B2 (en) 2004-08-24
US6211147B1 (en) 2001-04-03
US20040192606A1 (en) 2004-09-30
EP0845992A4 (en) 2000-04-19
DE69624925D1 (de) 2003-01-02
AU6777196A (en) 1997-03-12
ATE228004T1 (de) 2002-12-15

Similar Documents

Publication Publication Date Title
ES2187667T3 (es) Uso de relaxina para estimular angiogenesis.
DE297436T1 (de) Behandlung von hyperhidrose, ichtyosis und faltenbildung.
NO910340D0 (no) Topiske preparater for behandling av menneskenegler.
ATE111735T1 (de) Verwendung des wirkstoffs azelastin und glycerinethern zur bekämpfung von psoriasis- erkrankungen.
ID21948A (id) Penggunaan 1-hidroksi-2piridon untuk pengobatan infeksi-infeksi kulit
FI864570A0 (fi) Terapeutiskt anvaendbar foerening.
ES2195000T3 (es) Composicion farmaceutica.
ES2134184T3 (es) Empleo de etisterona para el tratamiento topico del acne o de la alopecia androgenetica.
ID21874A (id) Penggunaan 1-hidroksi-2-piridon untuk pengobatan infeksi urap kulit
ES2066096T3 (es) 4-bencil-5-fenil-2,4-dihidro-3h-1,2,4-triazol-3-onas y su uso como anticonvulsivos.
DK325387A (da) 4-benzyloxy-3-pyrrolin-2-on-1-yl-acetamid samt dets fremstilling og anvendelse
ATE109978T1 (de) Verwendung von purpuromycin zur behandlung von vaginalinfektionen.
ITTO930024A0 (it) Composizione per accelerare la rimarginazione di ferite
ITMI912466A1 (it) Uso di 1, 2 dipalmitoil-l-alfa-fosfatidil-n, n-dimetiletanolammina, in composizioni dermatologiche
DE69737088D1 (de) Therapeutisches agens zur behandlung von fiv infektionen
DE3777779D1 (de) Behandlung des haares.
BR9812489A (pt) Uso de 6,7-substituìdas-2-aminotetralinas adequadas para a preparação de uma composição farmacêutica para o tratamento terapêutico de patologias inflamatórias e/ou autoimunes
ES555245A0 (es) Perfeccionamientos en aparatos para el tratamiento humedo de tejidos
FR2584605B1 (fr) Application du n-(1-allyl-2-pyrrolidinylmethyl) 2-methoxy 4-amino 5-methylsulfamoyl benzamide dans le traitement de la maladie de parkinson
IT8622024V0 (it) Tampone preconfezionato e sterilizzato per la medicazione di ferite relativamente grandi.
IT1274015B (it) Uso del ceruletide (takus) nel trattamento della psoriasi
ITMI920333A1 (it) Uso di sostanze parasimpaticomimetiche dirette per la terapia del dolore.
NO981020L (no) Transdermalt terapautisk system for silatranforbindelser
MX9204845A (es) Combinaciones de compuestos de cloruro de amonio ymetodo para el tratamiento de infecciones virales.
ITRM920516A1 (it) Composizione e suo uso per il trattamento terapeutico di affezioni dermatitiche, particolarmente la psoriasi.